Synergistic anti-tumor effects of combined IL-1/IFN-α/β therapy in mice injected with met astatic friend erythroleukemia cells

✍ Scribed by F. Belardelli; L. Gabriele; E. Proietti; P. Sestili; M. Peretti; C. Rozera; I. Gresser

• Publisher: John Wiley and Sons
• Year: 1991
• Tongue: French
• Weight: 509 KB
• Volume: 49
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910490222

✦ Synopsis

Abstract

Peritumoral injection of relatively low doses of either mouse interferon (IFN)‐α/β (10,000‐20,000 unit/injection) or of recombinant human interleukin‐I (IL‐1) β (125‐250 ng/ injection) in mice transplanted S.C. with Friend erythroleukemia cells (FLC) resulted in some inhibition of primary tumor growth, inhibition of liver and splenic metastases and increased survival time. A synergistic anti‐tumor effect was observed in mice injected with both IL‐l and IFN‐α/β. Highly purified mouse IFN‐β also exerted a synergistic anti‐tumor effect when combined with IL‐I‐β in mice injected with FLC. The anti‐tumor action of IL‐I/IFN was markedly reduced in mice treated with antibodies to CD4 antigens. Antibodies to asialo‐GM~1~ also diminished the anti‐tumor effect by the combined cytokine treatment. The combined IL‐I/IFN therapy was effective in NK‐deficient bg/bg mice, although the extent of the anti‐tumor response in these mice was less than that observed in bg/+ mice.